Patient enrolment


The MASTER DAPT trial started operations on October 3rd, 2016 with first Ethics Approval achieved after 2.5 months at the Research and Ethics Committee King Fahd Armed Forces Hospital Jeddah Saudi-Arabia. All participating sites were active after 34 months from start of activities.

The MASTER DAPT trial included 140 sites in 30 countries. Sites were distributed as follows:

Country

Sites

FR

16

NL

11

CH

 7

BE

 6

GB

12

IT

16

EE

 1

ES

10

JP

13

BG

 4

PL

 5

IN

 4

AU

 5

RS

 3

CZ

 2

MK

 1

IL

 4

HU

 2

SG

 2

AT

 2

BD

 1

VN

 1

DE

 2

AR

 3

SA

 1

KR

 1

DK

 1

SE

 2

BH

 1

PT

 1

The first patient was enrolled on 04/04/2017 at Scheper Ziekenhuis, Emmen, the Netherlands with Dr. G. Jessurun being the site Principal Investigator. Enrolment of all participants, amounting to 4578 was achieved on December 10th, 2019 at Policlinico Casilino, Rome, Italy with Dr. M. Donahue being the site Principal Investigator. The achieved rate of enrolment was 1.0 patient/site/month.

Enrolment per country was distributed as follows:

Country

Total randomized

FR

576

NL

539

CH

499

BE

301

GB

279

IT

276

EE

259

ES

196

JP

187

BG

183

PL

177

IN

148

AU

142

RS

138

CZ

134

MK

120

IL

100

HU

68

SG

47

AT

44

BD

39

VN

25

DE

25

AR

16

SA

16

KR

15

DK

13

SE

8

BH

7

PT

1

The top 3 enrolling sites in the MASTER DAPT were:

  1. Inselspital, Bern, Zwitserland, Dr. A. Moschovitis (308 patients)
  2. North-Estonia Medical Centre, Tallinn, Estonia, Dr. P. Laanmets (259 patients)
  3. Maasstad hospital, Rotterdam, the Netherlands, Dr. P. Smits (233 patients)

The MASTER DAPT achieved complete follow-up on Q1 2021, and results are expected on Q3 2021.